0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

Defusing adverse effects of anticancer drugs

Beverly Merz; Tom Hager
JAMA. 1983;250(4):459. doi:10.1001/jama.1983.03340040011008.
Text Size: A A A
Published online

ABSTRACT

Doxorubicin hydrochloride and daunorubicin hydrochloride, two of the most potent drugs in the anticancer arsenal, share, in addition to bone marrow suppression, another serious—sometimes fatal—adverse effect: cardiotoxicity. Recently, however, research at several institutions has begun to yield ways to eliminate this drawback and, in some cases, increase the drugs' potencies in the process.

Researchers at SRI International, Menlo Park, Calif, and Adria Laboratories, Inc, Dublin, Ohio, have developed a doxorubicin derivative that appears to be orders of magnitude more potent than the parent molecule yet free of its main side effect. The newly synthesized molecule, 3′-deamino-3′-(3-cyano-4-morpholinyl) doxorubicin, called "A-489," has been tested against two forms of leukemia and a solid tumor in mice, as well as in DNA/RNA synthesis inhibition trials in cultured tumor cells. The studies indicate that the optimum dose of A-489 is 600 times lower than that of doxorubicin. Results are the same whether the substance is

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Figures

Tables

References

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();